A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

NCT06585969 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Lack of funding

Conditions

Metastatic Breast Cancer
ER-positive Breast Cancer
Luminal B
Her2 Enriched
Basal Like

Interventions

DRUG: Trastuzumab deruxtecan (T-DXd)
DRUG: Ribociclib with ET
DRUG: Abemaciclib with ET

Sponsor

Danish Breast Cancer Cooperative Group